Renaissance Technologies
CRXT

Renaissance Technologies’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Renaissance Technologies’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-122,277
Closed -$47K – 4578
2022
Q2 		$47K Buy
122,277
+87,577
+252% +$61.3K ﹤0.01% 4006
2022
Q1 		$52K Buy
+34,700
New +$44.1K ﹤0.01% 3908

Other funds holding CRXT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies's CRXT Position: Q3 2022 in Review

Renaissance Technologies sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 122,277 shares — an estimated $47K sold.

Renaissance Technologies first reported a position in CRXT in Q1 2022 and held it in 2 quarters. The position peaked at $52K in Q1 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

  • Renaissance Technologies reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Renaissance Technologies sold 122,277 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $47K.
  • Renaissance Technologies first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Renaissance Technologies's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $52K in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.